Sign In
Buy CERT
$5.60
-0.0200 (-0.356%)
At Close: Jun 03, 2026
Certara Looks Positioned For Increased Growth In 2022
03:04pm, Wednesday, 02'nd Feb 2022
Certara went public in December 2020, raising $337 million in an IPO.
Can Certara, Inc. (CERT) Run Higher on Rising Earnings Estimates?
01:50pm, Tuesday, 04'th Jan 2022
Certara, Inc. (CERT) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Can Certara, Inc. (CERT) Climb 35% to Reach the Level Wall Street Analysts Expect?
11:34am, Tuesday, 04'th Jan 2022
The average of price targets set by Wall Street analysts indicates a potential upside of 35.1% in Certara, Inc. (CERT). While the effectiveness of this highly sought-after metric is questionable, the
Certara (CERT) Stock: Why The Price Dropped Today
09:16am, Thursday, 18'th Nov 2021
The stock price of Certara Inc (NASDAQ: CERT) fell by over 10% pre-market today. This is why it happened.
Certara Inc. (CERT) CEO William Feehery on Q3 2021 Results - Earnings Call Transcript
08:43pm, Tuesday, 09'th Nov 2021
Certara Inc. (CERT) CEO William Feehery on Q3 2021 Results - Earnings Call Transcript
Certara to Report Third Quarter 2021 Financial Results on November 9th, 2021
08:00am, Tuesday, 19'th Oct 2021
PRINCETON, N.J., Oct. 19, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the third quarter of 2021
Certara Appoints Drayton T. Virkler as Chief Commercial Officer
08:00am, Tuesday, 05'th Oct 2021
Experienced commercial leader brings 20 years of experience in pharma Experienced commercial leader brings 20 years of experience in pharma
Certara Launches New Synchrogenix™ Writer Software to Accelerate the Regulatory Submission Process
04:30pm, Thursday, 30'th Sep 2021
Cloud-based and validated regulatory software automates and advances quality of patient narratives Cloud-based and validated regulatory software automates and advances quality of patient narratives
Certara: Global Biosimulation Firm Positions Itself For Stability Into The Long Term
04:10am, Wednesday, 29'th Sep 2021
Certara: Global Biosimulation Firm Positions Itself For Stability Into The Long Term
Certara Announces New Clinical Science Group and Adds Senior Scientific Experts
08:00am, Wednesday, 22'nd Sep 2021
Multi-Disciplinary Expansion and New Appointments Grow Capacity and Capabilities Multi-Disciplinary Expansion and New Appointments Grow Capacity and Capabilities
Certara Awarded FDA Grant to Further Advance Virtual Bioequivalence Assessments of Generic Medicines Using Biosimulation
08:00am, Monday, 20'th Sep 2021
Represents Fourth FDA Grant for Simcyp MechDermA™ Model for Virtual Bioequivalence Represents Fourth FDA Grant for Simcyp MechDermA™ Model for Virtual Bioequivalence
PRINCETON, N.J., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it closed its public offering of 23,000,000 shares of common st
CERT Stock: Why It Is Trading Lower Today
11:00am, Thursday, 09'th Sep 2021
The stock price of Certara Inc (NASDAQ: CERT) dropped over 7% pre-market this morning. This is why it happened.
Certara Stock Under Pressure On Equity Raise Of $140M At 12% Discount
06:32am, Thursday, 09'th Sep 2021
Certara Inc (NASDAQ: CERT) has priced its previously announced underwritten public offering of 4.5 million shares at $31.00 per share for gross proceeds of $139.5 million. The offer price represent
Certara Announces Pricing of Public Offering of Common Stock
09:01pm, Wednesday, 08'th Sep 2021
PRINCETON, N.J., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the pricing of its underwritten public offering of shares of its com
